This statistic reveals the revenues generated by top product Revlimid from 2008 to 2023. In 2023, one of the leading cancer drugs globally generated revenues of about six billion U.S. dollars. Revenues dropped dramatically since the launch of a generic version of the drug in March 2022. Revlimid was developed by Celgene Corporation, a former company headquartered in Summit, New Jersey. The company was specialized on drug manufacturing for cancer and inflammatory disorders. During 2019, the company was acquired by Bristol Myers Squibb.
Revenue of top product Revlimid from 2008 to 2023
(in million U.S. dollars)
The statistic was assembled from several annual reports.
* Transition year (BMS' acquisition of Celgene); value is rounded.
** Year of first generic version on the market.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Bristol-Myers Squibb. (February 13, 2024). Revenue of top product Revlimid from 2008 to 2023 (in million U.S. dollars) [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/1269411/revenues-of-revlimid/
Bristol-Myers Squibb. "Revenue of top product Revlimid from 2008 to 2023 (in million U.S. dollars)." Chart. February 13, 2024. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1269411/revenues-of-revlimid/
Bristol-Myers Squibb. (2024). Revenue of top product Revlimid from 2008 to 2023 (in million U.S. dollars). Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1269411/revenues-of-revlimid/
Bristol-Myers Squibb. "Revenue of Top Product Revlimid from 2008 to 2023 (in Million U.S. Dollars)." Statista, Statista Inc., 13 Feb 2024, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1269411/revenues-of-revlimid/
Bristol-Myers Squibb, Revenue of top product Revlimid from 2008 to 2023 (in million U.S. dollars) Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1269411/revenues-of-revlimid/ (last visited November 10, 2024)
Revenue of top product Revlimid from 2008 to 2023 (in million U.S. dollars) [Graph], Bristol-Myers Squibb, February 13, 2024. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/1269411/revenues-of-revlimid/
